EUVIMEDEUVIMED entdecken
Crossref

Eudragit RS100 nanoparticles for sustained release of Cefpodoxime Proxetil: preparation, pharmaceutical characterization, and in-vitro drug release studies

Jaya Verma, Saurabh Shekhar, Monika ,, Vikas Jhawat, Mahima Chauhan, Sonali, ,, Rahul Pratap Singh

Nanomedicine Journal · 2026-01 · 13 (1) · 210-223

DOI: 10.22038/nmj.2025.82111.2045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanomedicine Journal, 2026-01. Verfasst von Jaya Verma und 7 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective(s): The primary objective of this study was to develop a sustained-release formulation of cefpodoxime proxetil (CP) using the polymer Eudragit RS 100 (ERS100).Materials and Methods: Pluronic F127 (PF127) was incorporated as an amphiphilic surfactant to enhance product stability. Preformulation evaluations, including UV-visible spectroscopy and Fourier-transform infrared spectroscopy (FTIR), were performed to assess the compatibility of the drug, polymer, and their 1:1 mixture. Nanoparticles were formulated using the solvent evaporation technique, followed by continuous stirring of the emulsion during the removal of the organic solvent.

Results

The optimized formulation exhibited a particle size of less than 200 nm and an entrapment efficiency of 81.45 ± 0.891% for CP. In vitro drug release studies revealed sustained-release behavior, with the release kinetics best fitting the Higuchi (R² = 0.9757) and Hixson–Crowell (R² = 0.9707) models. Stability studies confirmed compliance with ICH guidelines regarding temperature and humidity conditions. These findings underscore the potential of CP-loaded nanoparticles as efficient carriers for sustained drug delivery, particularly targeting lung tissues.

Conclusion

The developed ERS100-based CP nanoparticles offer promising therapeutic benefits, including improved patient adherence through extended drug release intervals.

Schlagwörter

cefpodoxime proxetildrug delivery systemsdrug stabilityeudragit rs100nanoparticles

Zitieren

APA

Verma, J., Shekhar, S., ,, M., Jhawat, V., Chauhan, M., Sonali, ,, & Singh, R. P. (2026). Eudragit RS100 nanoparticles for sustained release of Cefpodoxime Proxetil: preparation, pharmaceutical characterization, and in-vitro drug release studies. Nanomedicine Journal, 13(1), 210-223. https://doi.org/10.22038/nmj.2025.82111.2045

Vancouver

Verma J, Shekhar S, , M, Jhawat V, Chauhan M, Sonali, et al. Eudragit RS100 nanoparticles for sustained release of Cefpodoxime Proxetil: preparation, pharmaceutical characterization, and in-vitro drug release studies. Nanomedicine Journal. 2026;13(1):210-223. doi:10.22038/nmj.2025.82111.2045

BibTeX
@article{Verma2026,
  author = {Verma, Jaya and Shekhar, Saurabh and ,, Monika and Jhawat, Vikas and Chauhan, Mahima and Sonali and , and Singh, Rahul Pratap},
  title = {Eudragit RS100 nanoparticles for sustained release of Cefpodoxime Proxetil: preparation, pharmaceutical characterization, and in-vitro drug release studies},
  journal = {Nanomedicine Journal},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {210--223},
  doi = {10.22038/nmj.2025.82111.2045}
}
Kostenlos starten →